Bekämpfung von Alzheimer durch Schlaf und Bewegung (CASE)
Bekämpfung von Alzheimer durch Schlaf und Bewegung (CASE)
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Azizi A Seixas, PhD
- Telefonnummer: 3052431301
- E-Mail: Azizi.seixas@med.miami.edu
Studieren Sie die Kontaktsicherung
- Name: Debbie Chung, PhD
- Telefonnummer: 3052431301
- E-Mail: dxc1729@miami.edu
Studienorte
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami Hospitals
-
Kontakt:
- Azizi A Seixas, PhD
- Telefonnummer: 3052431301
- E-Mail: Azizi.seixas@med.miami.edu
-
Hauptermittler:
- Azizi A Seixas, PhD
-
Unterermittler:
- Alberto Ramos, MD
-
Kontakt:
- Debbie Chung, PhD
- Telefonnummer: 3052431301
- E-Mail: dxc1729@miami.edu
-
Unterermittler:
- Debbie Chung, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Aged 55-80 years at the time of the screening visit
- Able to ambulate safely and independently
- Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
- Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
- Able to operate a digital device like mobile phone or computer
- Able and willing to provide venous blood samples
- Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
- Able to self-report a history of cognitive changes or impairment
- Be cognitively able (including those with and without MCI) and willing to provide informed consent
- Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle
Exclusion Criteria:
- Severe mobility limitations that prevent safe participation in moderate exercise protocols
- Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
- Inability to complete intake screening procedures
- Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
- Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
- Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
- Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
- Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
- Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
- Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Sleep Only Group
Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. |
|
Aktiver Komparator: Exercise Only Group
Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off). |
Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
|
Aktiver Komparator: Exercise and Sleep Group
Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glycated Hemoglobin (HbA1c) Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Total Cholesterol Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Triglycerides Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-sensitivity C-reactive protein (hs-CRP) Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Low-Density Lipoprotein (LDL) Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
C-Peptides
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-Density Lipoprotein (HDL) Levels
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Cognitive Function
Zeitfenster: Up to 8 weeks
|
Cognitive function gauged from Altoida's Digital Neuro-Signatures |
Up to 8 weeks
|
|
Insulin Levels
Zeitfenster: Up to 8 weeks
|
Measured from blood sample |
Up to 8 weeks
|
|
Neurofilament light chain
Zeitfenster: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Total Sleep Duration
Zeitfenster: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
Slow Wave Sleep Duration
Zeitfenster: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
%Slow-wave Sleep
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Rapid Eye Movement Duration
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%REM
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Light Non-Rapid Eye Movement Duration
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%Light Non-Rapid Eye Movement Sleep
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Efficiency
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Onset Latency
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Restlessness (Restless Bouts/Hour during Sleep)
Zeitfenster: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Light Exposure
Zeitfenster: Up to Week 8
|
Measured by LYS Device |
Up to Week 8
|
|
Psychosocial Metrics
Zeitfenster: Up to Week 8
|
Measured by Questionnaires |
Up to Week 8
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Azizi A Seixas, PhD, University of Miami
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 20220931
- 20-01023 (Andere Kennung: NYU)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .